United States Patent 7,887,836 (Liposome-Encapsulated Vincristine) Claims Scope, Patent Estate, and US Generic/Biosimilar Entry Risk
Executive summary
US 7,887,836 is directed to a specific clinical use envelope for liposome-encapsulated vincristine (LE-vincristine): defined cancer indications (lymphoma, leukemia, myeloma), defined dosing (about 1.5 to about 2.4 mg/m²; with a narrower higher-dose bracket at ≥2.0 to 2.4 mg/m²), and tightly bounded formulation attributes (sphingomyelin/cholesterol molar ratios and vincristine concentration in the liposomes). Dependent claims further narrow to infusion duration, dosing interval, co-administration combinations, neurotoxicity counter-treatment, and a mixing/encapsulation process window (vincristine sulfate solution pH and concentration; liposome buffer pH; alkaline phosphate buffer pH shift). The enforceable scope is therefore strongest where the accused product matches all claim-defining parameters simultaneously: dose level, liposome composition ratio, and encapsulated drug concentration, plus (for process claims) preparation pH/concentration steps.
What patents protect liposome-encapsulated vincristine for lymphoma, leukemia, and myeloma in the US?
Immediate claim coverage (US 7,887,836)
The independent claims you provided establish three core protection “pillars”:
- Method of treatment (human; cancer selected from lymphoma/leukemia/myeloma)
- Dose and regimen (mg/m² window; and in dependent claims, schedule and infusion timing)
- Formulation-defined drug product characteristics (liposome composition ratio and encapsulated vincristine concentration)
Independent claim 1 scope
Claim 1 is a compound-parameter clinical method with these boundaries:
- Indications: lymphoma, leukemia, myeloma (in a human)
- Dose: about 1.5 mg/m² to about 2.4 mg/m²
- Liposome composition: sphingomyelin/cholesterol 75/25 to 50/50 mol%/mol%
- Encapsulated vincristine concentration: 0.10 to 0.50 mg/mL
Because the claim is “administering” a composition, enforceability hinges on whether the administered product has the required lipid ratio and encapsulated concentration, and whether the administered dose lies inside the mg/m² window.
Independent claim 2 scope
Claim 2 tightens the clinical and formulation subset:
- Indications: lymphoma/leukemia/myeloma
- Dose: ≥ about 2.0 mg/m² to about 2.4 mg/m²
- Liposome composition: sphingomyelin/cholesterol fixed at 55/45 mol%/mol%
- Encapsulated vincristine concentration: 0.10 to 0.50 mg/mL
This is narrower on the lipid ratio and narrower on dose lower bound relative to claim 1.
Dependent claims that materially narrow the capture net
- Concentration subrange:
- Claim 3: 0.15 to 0.20 mg/mL
- Claim 4: about 0.16 mg/mL
- Dose within claim 1 envelope:
- Claim 5: about 2.0 to about 2.4 mg/m²
- Disease state:
- Claim 6: relapsed or refractory
- Sub-indications:
- Claim 7: non-Hodgkin’s lymphoma (NHL)
- Claim 8: Acute lymphocytic leukemia (ALL)
- Additional lipid ratio options:
- Claim 9: 70/30 to 55/45
- Claim 10: exactly 55/45
- Administration route/timing:
- Claim 11: parenteral
- Claim 12: systemic by IV infusion
- Claim 13: infusion over 30 to 90 minutes
- Claim 14: about 60 minutes
- Claim 15: every 7 to 21 days
- Claim 16: every 1 to 28 days
- Claim 17: every 7 to 21 days (restates)
- Claim 18: every 14 days
- Claim 19: every 7 days
- Combination therapy:
- Claim 20: co-administered with at least one additional cancer therapy
- Claim 21: therapy examples including radiation, bone marrow transplant, hormone therapy, surgery, cyclophosphamide, doxorubicin, prednisone, taxanes, camptothecins, podophyllins, and combinations
- Claim 22: anti-tumor antibody
- Claim 23: antisense drug or anti-tumor vaccine
- Neurotoxicity co-treatment:
- Claim 24: co-administered with a treatment for neurotoxicity
- Specific amount:
- Claim 25: about 3.0 to about 6.0 mg of vincristine (note this is independent of mg/m² and can create separate infringement pathways depending on how the clinician doses across patient sizes)
- Taxane co-therapy and liposomal taxane:
- Claim 26: additional therapy is a taxane
- Claim 27: taxane is liposomal taxane
- Salt form:
- Claim 28: vincristine is vincristine sulfate
- Specific triple combination:
- Claim 29: co-administered with cyclophosphamide, doxorubicin, prednisone
- Process claim with pH and concentration steps:
- Claim 30: mixing vincristine sulfate in defined concentration and pH with empty liposomes in buffer pH ~4.0; then adding alkaline phosphate buffer with pH sufficient to raise mixture pH to produce LE-vincristine prior to administration (and fixing lipid ratio at 55/45 mol%)
Practical point for infringement mapping
US 7,887,836 contains both (i) use claims that look like product attribute claims tied to administration and (ii) a manufacturing/process-limited dependent claim (claim 30). That structure creates two separate enforcement vectors:
- Product matching for the method-of-use and formulation-limited claims
- Manufacturing step matching for the process-limited claim
What is the exact scope of US 7,887,836 claims in dosage, infusion interval, and liposome composition?
Short answer
The strongest claim coverage occurs where the administered LE-vincristine matches:
- dose within the claim-specific mg/m² windows
- lipid molar ratio (sphingomyelin/cholesterol) in the specified range (or exactly 55/45 for claim 2 and for claim 30)
- encapsulated vincristine concentration in the specified range (or in the narrower subranges of dependent claims)
- and where applicable, IV infusion duration and treatment schedule and/or combination regimen parameters.
Claim scope matrix (key parameters)
| Claim |
Indication coverage |
Dose range |
Sphingomyelin/Cholesterol (mol%) |
Encapsulated vincristine (mg/mL) |
Route/timing elements |
Other narrowing |
| 1 |
lymphoma/leukemia/myeloma |
~1.5 to ~2.4 mg/m² |
~75/25 to ~50/50 |
0.10 to 0.50 |
depends on dependents |
none |
| 2 |
lymphoma/leukemia/myeloma |
≥~2.0 to ~2.4 mg/m² |
55/45 fixed |
0.10 to 0.50 |
depends on dependents |
none |
| 3 |
depends on 1/2 |
(as in 1/2) |
(as in 1/2) |
0.15 to 0.20 |
- |
- |
| 4 |
depends on 1/2 |
(as in 1/2) |
(as in 1/2) |
~0.16 |
- |
- |
| 5 |
depends on 1 |
~2.0 to ~2.4 mg/m² |
(as in 1) |
(as in 1) |
- |
- |
| 6 |
depends on 1/2 |
(as in 1/2) |
(as in 1/2) |
(as in 1/2) |
- |
relapsed/refractory |
| 7 |
depends on 1/2 |
- |
- |
- |
- |
NHL |
| 8 |
depends on 1 |
- |
- |
- |
- |
ALL |
| 9 |
depends on 1 |
- |
70/30 to 55/45 |
- |
- |
- |
| 10 |
depends on 1 |
- |
55/45 fixed |
- |
- |
- |
| 11-19 |
depends on 1/2 |
(as in 1/2) |
(as in 1/2 or dependents) |
(as in 1/2 or dependents) |
parenteral; IV infusion; infusion duration; interval |
schedule varies |
| 20-24 |
depends on 1/2 |
- |
- |
- |
route/timing varies by dependents |
co-therapy; includes neurotoxicity treatment |
| 25 |
depends on 1 |
dose in mg not mg/m² |
- |
- |
- |
~3.0 to ~6.0 mg vincristine |
| 26-27 |
depends on 1 |
- |
- |
- |
- |
taxane; liposomal taxane |
| 28 |
depends on 1 |
- |
- |
- |
- |
vincristine sulfate |
| 29 |
depends on 1 |
- |
- |
- |
- |
cyclophosphamide + doxorubicin + prednisone |
| 30 |
depends on claim’s liposome attribute |
not explicitly stated beyond claim 2 lipid ratio |
55/45 fixed |
depends on encapsulation product outcome |
mixing steps; pH steps |
process: pH/concentration constraints |
When does US 7,887,836 lose exclusivity in the US, and what launch timing risks exist for generics?
Answer constrained by missing grant/filing chronology
US patent exclusivity (including statutory term and potential PTA/PTE adjustments) depends on the patent’s filing date, issue date, and any terminal disclaimers. With only the number and claim text provided, a complete and accurate exclusivity timeline cannot be produced.
What can be stated from the claim set
The claims are framed as method-of-use claims. That means even with patent term expiry, there may be enforcement questions only if the method claims are still asserted or if other patents in the family remain active. The commercial launch risk for a generic is therefore driven by:
- whether a generic product matches the lipid ratio and encapsulated vincristine concentration (product attribute match),
- whether the provider follows a practice that falls within claimed dose/schedule ranges (method practice match),
- and whether additional patents cover manufacturing steps or product compositions.
What is the Orange Book status of the LE-vincristine product covered by US 7,887,836?
No reliable determination from provided inputs
Orange Book listing status requires the specific FDA application number, NDC, and active ingredient presentation (and the FDA product name). Those inputs are not supplied. Without them, a complete and accurate Orange Book status statement cannot be made.
Which companies are likely implicated by US 7,887,836 liposome-encapsulated vincristine claims?
No reliable determination from provided inputs
Company implication depends on:
- the patent’s assignee(s),
- the FDA sponsor and NDA/BLA holder(s),
- the development history and known competitors,
- and any Paragraph IV filings and litigation dockets.
The patent’s assignee and the covered product identity are not provided, so a defensible company list cannot be generated.
How strong is the patent estate for liposome-encapsulated vincristine: what claim features improve enforceability?
Core strength factors
-
Tightly bounded formulation parameters
The claims require specific sphingomyelin/cholesterol molar ratios (including a fixed 55/45 point) and encapsulated vincristine concentration ranges. This reduces design-around options relative to broader “liposome-encapsulated vincristine” claims.
-
Dose level constraints
The independent claims include dose windows in mg/m² with a higher-dose bracket in claim 2. Dosing variability in clinical practice can become a key infringement lever for both sides.
-
Operational delivery constraints in dependents
Infusion duration (30 to 90 minutes; about 60 minutes) and dosing interval (every 7 to 21 days; every 14 days; every 7 days) make the method narrower. That narrows infringement to specific practice patterns, but it also creates clearer “non-infringing alternatives” if a competitor changes infusion interval.
-
Combination regimens and neurotoxicity counter-treatment
Dependent claims that require co-administration of additional therapies (including specific combinations and neurotoxicity treatment) can both strengthen leverage (if clinical practice matches) and weaken enforceability (if clinical protocols differ).
-
Process claim (claim 30) with pH and concentration steps
The encapsulation preparation steps provide a second infringement vector targeting manufacturing. If a competitor uses materially different pH/concentration steps, it can fall outside claim 30 even if the final product matches the use claims.
What generic entry risks exist for liposome-encapsulated vincristine under these claims?
Key risk mechanics
- A “generic” of liposome-encapsulated vincristine is likely judged through the lens of whether it is “the same drug product” for FDA purposes, but infringement against method claims turns on whether the administered and manufactured product falls within the parameterized formulation ranges.
- Claim 2’s fixed 55/45 ratio and the dependent vincristine concentration subranges (0.15-0.20 mg/mL; ~0.16 mg/mL) create potential non-infringing design-around if a competitor’s product operates outside those concentration and ratio windows.
Design-around opportunities implied by the claim language
- Shift lipid composition outside the specified mol% windows (for claim 2, outside fixed 55/45).
- Adjust encapsulated vincristine concentration outside 0.10-0.50 mg/mL or outside the narrower subranges (0.15-0.20; ~0.16).
- Alter dosing schedules and/or infusion duration so dependents 13-19 are avoided.
- If targeting claim 30, avoid the specified pH/concentration mixing and alkaline phosphate pH shift process window and use materially different encapsulation parameters.
What patent litigation affects US 7,887,836 and is there an enforceable settlement posture?
No reliable determination from provided inputs
Litigation status requires dockets, parties, and settlement dates. None are supplied.
How does US 7,887,836 compare with other liposomal vincristine patents and likely family members?
No reliable determination from provided inputs
A valid comparison needs the full patent family (continuations/divisionals), priority dates, and claim charts from the other family members. Only US 7,887,836 claim language is provided.
What formulations are protected by US 7,887,836: sphingomyelin/cholesterol windows and encapsulated vincristine concentration?
Protected formulation parameter space
- Sphingomyelin/cholesterol molar ratio range in claim 1: 75/25 to 50/50
- Fixed composition in claim 2: 55/45
- Additional ratio dependent windows:
- 70/30 to 55/45 (claim 9)
- exactly 55/45 (claim 10)
- Encapsulated vincristine concentration in independent claims: 0.10 to 0.50 mg/mL
- Narrow dependent concentration windows:
- 0.15 to 0.20 mg/mL (claim 3)
- about 0.16 mg/mL (claim 4)
Process-limited formulation production constraints (claim 30)
- First solution: vincristine sulfate 1 mg/mL to 5 mg/mL, pH 3.5 to 5.5
- Second solution: empty liposomes in buffer, pH about 4.0
- Liposomes: sphingomyelin/cholesterol 55/45
- Third solution: alkaline phosphate buffer; pH raised to produce encapsulated product prior to administration
How does the claim treat “relapsed/refractory” status, and does it create a separate infringement pathway?
Claim 6 adds an additional clinical condition: relapsed or refractory lymphoma/leukemia/myeloma. If the accused regimen is used in newly diagnosed patients outside that status, claim 6 is less likely to be directly infringed. However, because claim 6 is dependent, the strongest enforcement route depends on whether independent claims 1 or 2 are asserted without that additional condition.
Key Takeaways
- US 7,887,836 is parameter-driven: infringement depends on matching dose (mg/m²), lipid molar ratio (sphingomyelin/cholesterol), and encapsulated vincristine concentration ranges, plus optional dependent constraints (infusion timing, schedule, co-therapy).
- The formulation boundaries tighten design-around. Particularly probative targets include claim 2’s fixed 55/45 ratio and the dependent concentration subranges (0.15-0.20 mg/mL; ~0.16 mg/mL).
- The patent includes a process-limited manufacturing pathway (claim 30) tied to vincristine sulfate concentration and pH, empty liposome buffer pH, and alkaline phosphate pH raising. Competitors can reduce manufacturing risk by changing those parameters.
- Combination therapy and neurotoxicity co-treatment dependents can create practice-specific infringement. If clinical protocols omit those exact combinations or use different supportive care, dependent-claim infringement exposure narrows.
- A complete exclusivity/Orange Book/litigation assessment cannot be produced from claim text alone.
FAQs
1) Do the claims require the exact encapsulated vincristine concentration or a range?
They use ranges in the independent claims (0.10 to 0.50 mg/mL) and tighter ranges in dependents (0.15 to 0.20 mg/mL) and a specific value target (about 0.16 mg/mL).
2) Can a different sphingomyelin/cholesterol ratio avoid infringement?
For claim 2, the lipid ratio is fixed at 55/45, so moving outside that fixed molar ratio is a straightforward non-infringement lever if the competitor stays outside claim 1’s broader ratio band as well.
3) Are infusion schedule and duration required for infringement?
Not for independent claims 1 and 2 as written in your extract. Infusion duration and interval appear in dependent claims (13-19), so they matter only if those dependents are asserted.
4) Does the patent cover manufacturing steps?
Yes. Claim 30 is a dependent method/process claim that specifies vincristine sulfate concentration and pH, empty liposome buffer pH, and an alkaline phosphate pH shift, and fixes lipid ratio at 55/45.
5) Does “relapsed or refractory” create a separate claim bucket?
Yes. Claim 6 adds the relapsed/refractory status limitation as a dependent condition.
References (APA)
- United States Patent No. 7,887,836.
